APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Bookmark and Share
Published: 18 Dec 2019
Views: 831
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Prof Martine Piccart speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the updated six-year results from the APHINITY trial.

She gives a summary of the previous analyses, in which a statistically significant improvement in invasive disease-free survival, favouring the pertuzumab plus trastuzumab and chemotherapy arm.

Prof Piccart explains that this benefit has strengthened in the past six years and notes that a 4.5 percent absolute benefit has been seen in the node-positive patients. In addition, no new cardiac toxicities were detected.

She adds that the benefit of pertuzumab is independent from hormone-receptor status.

Prof Piccart believes that the achievement of this data is another step forward in eradicating this disease.

Watch the press conference here.

Read more about the study here